Company / Financials
International Stem Cell CORP Financials
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$9.1M
FY2025 · +0.2% YoY
Net Income
-$418.0K
FY2025 · -100.0% YoY
Profit Margin
-4.6%
FY2025 · net income / revenue
ROE
-
FY2025 · return on equity
Total Assets
$4.8M
FY2025
Total Debt
-
FY2025
Equity
-$4.1M
FY2025
ROA
-8.7%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -18.18 (distress zone, below 1.23 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$9.1M+0.2% YoYNet Income HistoryProfit after all expenses and taxes-$418.0K-100.0% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$4.0M+7.1% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$267.0K-292.6% YoYSG&A Expense HistorySelling, general, and administrative expenses$3.5M+0.5% YoYR&D Expense HistoryResearch and development spending$684.0K+4.1% YoYInterest Expense HistoryCost of borrowing and debt obligations$151.0K+4.1% YoYIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$0.03-50.0% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$0.03-50.0% YoY